IGF-1 DES vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
IGF-1 DESGLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- IGF-1 DES (also written DES(1-3)IGF-1) is a truncated form of IGF-1 missing the first three amino acids of the N-terminus. This structural change dramatically reduces its affinity for IGF binding proteins (IGFBPs), meaning a far greater fraction remains in its free, active form. IGF-1 DES is estimated to be 10x more potent than standard IGF-1 LR3 at the receptor level locally, making it particularly effective for site-specific muscle growth when injected intramuscularly.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- ~20–30 minutes (very short — designed for local action)
- ~13 hours (once-daily dosing)
- Admin Route
- IM, SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 20–50 mcg per injection site
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once daily, post-workout
- Once daily
- Key Benefits
- Estimated 10x greater potency at the receptor vs IGF-1 LR3 locally
- Minimal IGFBP binding — nearly all active upon injection
- Highly localized muscle growth effect when injected intramuscularly
- Activates satellite cells for muscle fiber hyperplasia potential
- Synergistic with GH peptides in post-workout anabolic protocols
- Shorter half-life reduces systemic exposure vs IGF-1 LR3
- Useful for site-specific muscle development
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Hypoglycemia (most significant risk — especially post-workout)
- Localized muscle swelling at injection site
- Potential for jaw/organ growth (acromegalic effects) with prolonged high-dose use
- Carpal tunnel syndrome with high doses
- +1 more
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —